Tas-102
Desmoid Tumor
Memorial Sloan Kettering Cancer CenterunclassifiedPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Desmoid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
su011248 Memorial Sloan Kettering Cancer Center | Phase 2 | B |
Nab-Rapamycin Sarcoma Oncology Research Center, LLC | Phase 1/2 | CCC |
Nirogacestat | D |
Same molecule, other indications
Tas-102 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →